30 Mar

Novartis Has Developed a Robust Innovation Strategy

WRITTEN BY Margaret Patrick

Multipronged strategy

To effectively capitalize on the growing demand for new drugs while controlling pricing risks, Novartis (NVS) plans to implement a multipronged strategy. The strategy involves rethinking all aspects of its value chain, from the way it develops new drugs to the way it sells these therapies to the way it operates across the world. Novartis calls this exercise “reimagining medicine.”

If the company successfully implements its strategy, its share price could see a boost, as could the price of the Vanguard FTSE All-World ex-US ETF (VEU). Novartis makes up ~0.75% of VEU’s total portfolio holdings.

Novartis Has Developed a Robust Innovation Strategy

Innovation strategy

To develop more effective and differentiated therapies, Novartis has been actively involved in developing multiple new technologies. In its second-generation Immunotherapy segment, the company is currently working on 11 clinical assets and two pre-clinical assets.

In 1H17, Novartis is expected to file an application with the FDA seeking approval for an investigational chimeric antigen receptor T cell (or CAR-T) therapy, CTL019, for pediatric patients suffering with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL).

In 2H17, the company is expected to file an application for CTL019 in relapsed or refractory diffuse large B-cell lymphoma (or DLBCL) indications.

Further, Novartis is also actively working on CRISPR-based (clustered regularly interspaced short palindromic repeats) targeted genome editing to develop a therapy for sickle cell disease.

These innovative research programs should enable Novartis to pose solid competition to other oncology players such as Pfizer (PFE), Merck & Co. (MRK), and Bristol-Myers Squibb (BMY) in future years.

In the next article, we’ll discuss Novartis’s growth strategy in greater detail.

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

14 Jun

Why Kimberly-Clark Stock May Stop Rising

WRITTEN BY Amit Singh

Kimberly-Clark (KMB) stock has risen 20.5% this year, boosted by the company’s better-than-expected sales and earnings during its last reported quarter. However, its stock could stop climbing. Here's why.

172.31.71.127